VERTEX PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 397.5 USD | -0.06% |
|
+0.81% | -2.31% |
Chart calendar Vertex Pharmaceuticals Incorporated
970a222.hp7s9VAMABDIXZjBglfzNI2TsaRQi_x9IWs_8pJSdKE._sm7gwM9WCOpFPGQ4wWKVtnp-8skz60ySRNVouETOtXk3YiACklUZIU62Q~c52d45e51dd6cb67d877a109a8acdf77
Upcoming events on Vertex Pharmaceuticals Incorporated
Past events on Vertex Pharmaceuticals Incorporated
| 10/04/2024 21:30 | Acquisition of Alpine Immune Sciences Inc by Vertex Pharmaceuticals Incorporated Call |
| 11/03/2024 20:00 | Leerink Partners Global Biopharma Conference |
| 05/03/2024 15:30 | TD Cowen Health Care Conference |
| 05/02/2024 21:30 | Q4 2023 Earnings Call |
| 05/02/2024 21:01 | Q4 2023 Earnings Release |
| 30/01/2024 13:00 | VX-548 Phase 3 Study Results Call |
| 08/01/2024 16:15 | JPMorgan Healthcare Conference |
| 13/12/2023 13:00 | VX-548 Phase 2 Study Results Call |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract No:4997 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract No:4999 |
| 12/12/2023 01:00 | American Society of Hematology Meeting - Abstract Number #1053 |
| 12/12/2023 00:45 | American Society of Hematology Meeting - Abstract Number #1052 |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract No:3900 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract No:3678 |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Abstract No:3674 |
| 14/11/2023 08:30 | Jefferies London Healthcare Conference - Fireside Chat |
| 09/11/2023 17:00 | UBS BioPharma Conference - Fireside Chat |
| 06/11/2023 21:30 | Q3 2023 Earnings Call |
| 06/11/2023 21:01 | Q3 2023 Earnings Release |
| 13/09/2023 16:30 | Morgan Stanley Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 4 163 3 759 10.74% | 6 206 6 159 0.76% | 7 574 7 502 0.97% | 8 931 8 933 -0.03% | 9 869 9 861 0.08% | 10 723 |
|
EBITDA Million USD | Released Forecast Spread | 1 893 1 770 6.92% | 3 601 3 649 -1.33% | 4 470 4 490 -0.46% | 4 941 5 101 -3.12% | 4 556 4 734 -3.75% | 5 298 |
|
EBIT Million USD | Released Forecast Spread | 1 786 1 609 11.02% | 3 491 3 471 0.58% | 4 344 4 345 -0.02% | 4 793 4 832 -0.81% | 4 375 4 461 -1.94% | 4 971 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 1 395 964 44.64% | 3 117 2 891 7.82% | 2 730 2 761 -1.12% | 4 232 4 155 1.86% | 4 380 4 415 -0.8% | 4 838 |
|
Net income Million USD | Released Forecast Spread | 1 177 796 47.91% | 2 712 2 608 3.99% | 2 342 2 295 2.07% | 3 322 3 287 1.06% | 3 620 3 574 1.28% | 3 857 |
|
EPS USD | Released Forecast Spread | 4,51 3,08 46.48% | 10,3 9,87 4.24% | 9,01 8,80 2.4% | 12,8 12,8 0.17% | 13,9 13,7 1.52% | 14,9 |
| Announcement Date | 30/01/20 | 01/02/21 | 26/01/22 | 07/02/23 | 05/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2 073 2 007 3.29% | 2 098 2 074 1.14% | 2 196 2 132 3.03% | 2 334 2 227 4.82% | 2 303 2 303 -0.01% | 2 375 2 336 1.67% | 2 493 2 421 3% | 2 484 2 502 -0.73% | 2 518 2 515 0.12% | 2 579 | 2 652 | 2 709 | 2 778 | 2 691 |
|
EBITDA Million USD | Released Forecast Spread | 1 215 1 255 -3.17% | 1 210 1 285 -5.81% | 1 256 | 1 277 | 1 285 | 1 250 | ||||||||
|
EBIT Million USD | Released Forecast Spread | 1 124 1 126 -0.15% | 1 167 1 188 -1.82% | 1 187 1 179 0.67% | 1 289 1 210 6.55% | 1 150 1 197 -3.94% | 902 971 -7.11% | 1 148 1 246 -7.89% | 1 173 1 239 -5.32% | 1 151 1 237 -6.9% | 1 201 | 1 224 | 1 240 | 1 270 | 1 326 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 871 908 -4.05% | 955 995 -3.99% | 1 024 994 3.05% | 1 176 1 038 13.29% | 1 077 990 8.81% | 892 850 4.85% | 1 162 1 132 2.56% | 1 179 1 136 3.76% | 1 148 1 199 -4.3% | 1 185 | 1 203 | 1 223 | 1 229 | 1 286 |
|
Net income Million USD | Released Forecast Spread | 770 720 7% | 762 801 -4.8% | 811 799 1.47% | 931 820 13.42% | 819 779 5.08% | 700 677 3.43% | 916 895 2.29% | 1 035 909 13.87% | 969 952 1.74% | 947 | 960 | 971 | 961 | 1 016 |
|
EPS USD | Released Forecast Spread | 3,00 2,76 8.61% | 2,96 3,14 -5.62% | 3,13 3,07 1.98% | 3,59 3,27 9.92% | 3,15 3,09 1.86% | 2,69 2,67 0.78% | 3,52 3,43 2.58% | 3,97 3,48 14.23% | 3,71 3,57 4.04% | 3,68 | 3,72 | 3,77 | 3,80 | 3,85 |
| Announcement Date | 26/01/22 | 05/05/22 | 04/08/22 | 27/10/22 | 07/02/23 | 01/05/23 | 01/08/23 | 06/11/23 | 05/02/24 | - | - | - | - | - |
More events
Past sector events for Vertex Pharmaceuticals Incorporated
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
- Calendar Vertex Pharmaceuticals Incorporated
